Search Results

You are looking at 51 - 60 of 497 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Nadeem R. Abu-Rustum and Yukio Sonoda

-sparing adjuvant therapy in patients with node-positive disease. The authors' current selection criteria for fertility-sparing radical trachelectomy are listed in Table 1 . Patients are selected for a laparoscopic vaginal approach (Dargent operation) if they are

Full access

Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, and Daniel H. Ahn

noninferiority of 3 months of adjuvant therapy in the overall population, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer include the recommendation of 3 to 6 months of adjuvant chemotherapy based on risk stratification. 8

Full access

Elizabeth Reed, Robin M. Lally, and Roksana Zak

unavailable (n=66). Eight clinical pathways based on ER, PR, and HER2 status were developed to guide treatment, considerations, evidence-based neoadjuvant and adjuvant therapy, and survivorship care. Pathways, with associated educational webinars and links to

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

/CTSU 49907 [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 507 . 31 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19

Full access

George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale

Cancers allowed the authors to create a system that could be used to examine quality across the spectrum of CRC care, from diagnosis through neoadjuvant therapy, surgery, adjuvant therapy, and surveillance or end-of-life care. The tool had important

Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

category 1 recommendations for adjuvant therapy. 9 Despite these consensus recommendations, studies have shown that, outside of the clinical trial setting, many patients do not go on to receive adjuvant chemotherapy. 10 – 13 Variables shown to affect the

Full access

Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami

into the perinodal tissues beyond the lymph node capsule—extranodal extension (ENE)—after SNB with a positive result would allow a more appropriate use of adjuvant therapy for those most likely to benefit, while also minimizing the morbidity for

Full access

Robert E. Smith Jr.

fluorouracil and folinic acid in B2 colon cancer . J Clin Oncol 1999 ; 17 : 1356 – 1363 . 54. Gill S Loprinzi CL Sargent DJ . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much

Full access

Ghadeer Olleik, Wassim Kassouf, Armen Aprikian, Jason Hu, Marie Vanhuyse, Fabio Cury, Stuart Peacock, Elin Bonnevier, Ebba Palenius, and Alice Dragomir

decision regarding adjuvant therapy. 37 , 92 Seven studies were found to have clinical utility evidence ( Figure 3 , supplemental eTable 2 ) on Decipher after prostatectomy, 36 , 55 – 57 , 76 – 78 and none were found on its use after a positive biopsy

Full access

Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force

NSABP B-31 and NCCTG N9831 trials of adjuvant therapy in breast cancer. From Romond et al. 19 ; with permission. HER2 Testing: Summary of Clinical Issues The use of HER2 tumor biomarker status in clinical decision-making ( Figure 1 ) has been limited by